Positive Predictive Value

The probability that subjects with a positive screening test truly have the disease.

Positive Predictive Value (PPV) is a statistical measure used to assess the accuracy of a diagnostic test or screening tool. It represents the probability that a subject who tests positive truly has the target condition or disease. In clinical trials and medical technology evaluations, PPV serves as a primary indicator of how reliable a positive result is in real-world clinical practice. While related metrics like sensitivity and specificity measure a test's performance in isolated laboratory settings, PPV is highly dependent on the prevalence of the condition within the tested population. If a disease is extremely rare, even a highly specific test will yield a large number of false positives relative to true positives, resulting in a low PPV. Conversely, testing a high-risk population increases the PPV of the exact same diagnostic tool. For healthcare and biotechnology investors, PPV is a critical commercial viability metric. A low PPV means doctors will encounter frequent false positives, leading to unnecessary follow-up procedures, patient anxiety, and wasted healthcare resources. Consequently, diagnostic products with low PPV struggle to secure insurance reimbursement and clinical adoption, whereas a high PPV supports a strong value proposition for healthcare providers and payers.

A biotechnology company develops a diagnostic test for a rare disease. In a clinical trial of 10,000 patients, 150 patients test positive. Out of these 150 positive results, subsequent gold-standard testing confirms that 90 patients actually have the disease, while 60 do not (false positives). The Positive Predictive Value is calculated as 90 / (90 + 60) = 90 / 150 = 60%.